The PTF1 (pancreas transcription factor 1) complex is a master regulator of differentiation of acinar cells, responsible for the production of digestive enzymes. In the adult pancreas, PTF1 contains two pancreas-restricted transcription factors: Ptf1a and Rbpjl. PTF1 recruits P/CAF [p300/CREB (cAMPresponse-element-binding protein)-binding protein-associated factor] which acetylates Ptf1a and enhances its transcriptional activity. Using yeast two-hybrid screening, we identified ICAT (inhibitor of β-catenin and Tcf4) as a novel Ptf1a interactor. ICAT regulates the Wnt pathway and cell proliferation. We validated and mapped the ICAT-Ptf1a interaction in vitro and in vivo. We demonstrated that, following its overexpression in acinar tumour cells, ICAT regulates negatively PTF1 activity in vitro and in vivo. This effect was independent of β-catenin and was mediated by direct binding to Ptf1a and displacement of P/CAF. ICAT also modulated the expression of Pdx1 and Sox9 in acinar tumour cells. ICAT overexpression reduced the interaction of Ptf1a with Rbpjl and P/CAF and impaired Ptf1a acetylation by P/CAF. ICAT did not affect the subcellular localization of Ptf1a. In human pancreas, ICAT displayed a cell-type-specific distribution; in acinar and endocrine cells, it was nuclear, whereas in ductal cells, it was cytoplasmic. In ductal adenocarcinomas, ICAT displayed mainly a nuclear or mixed distribution and the former was an independent marker of survival. ICAT regulates acinar differentiation and it does so through a novel Wnt pathwayindependent mechanism that may contribute to pancreatic disease.
INTRODUCTION
The transcription factor Ptf1a plays a crucial role in development and differentiation as part of the PTF1 (pancreas transcription factor 1) complex [1] [2] [3] . Acinar cells are the most abundant cell type in the pancreas; they specialize in high-level digestive enzyme production and play an important role in diseases of the exocrine pancreas, including pancreatitis and pancreatic cancer [4, 5] . PTF1 is a master regulator of the acinar differentiation programme [1, 6, 7] . In the adult mature pancreas, three proteins constitute PTF1: the ubiquitous bHLH (basic helix-loop-helix) factors E2A or HEB (also known as Tcf12), the acinar-specific bHLH protein Ptf1a [6, 8] , and the pancreas-specific protein Rbpjl which is homologous to Rbpj [9, 10] . PTF1 also mediates the developmental function of Ptf1a. However, at this stage, the third component is Rbpj whose function is Notch-independent [2, 3, 11] . Importantly, the embryonic PTF1 complex regulates positively the Rbpjl promoter and expression of this protein displaces Rbpj, leading to the adult PTF1 complex, which, in turn, activates the Ptf1a locus in a positive regulatory feedback loop [11] . The adult PTF1 complex is required to drive high-level enzyme expression: deletion of a single allele of Ptf1a results in altered acinar homoeostasis [12] and Rbpjl inactivation is associated with a dramatic reduction in the expression of mRNAs coding for digestive enzymes as well as with the acquisition of a more plastic cellular state in which a subset of hepatic genes is expressed in the pancreas [7] . The high-level expression of digestive enzymes driven by the PTF1 complex, is also dependent, at least in vitro, on the acetylation of Ptf1a by P/CAF [p300/CREB (cAMP-responseelement-binding protein)-binding protein-associated factor], a histone acetyltransferase that uses both histone and transcription factors as substrates [13] . In addition, high-level Ptf1a expression couples cell differentiation with quiescence in acinar cells in a manner independent of acetylation [12, 13] .
Whereas PTF1 is crucial for the activation of the acinar cell programme and its down-regulation is strongly associated with the loss of expression of digestive enzymes [1, 2, 14] , there is evidence that the fine tuning of acinar cell function is also dependent on other transcription factors including Mist1 (involved in zymogen granule packaging and secretion), Hnf1a, Nr5a2, Gata6 and Xbp1 [15] [16] [17] [18] [19] [20] that contribute to 'complete' differentiation and stabilize the acinar phenotype.
The Wnt pathway is a crucial regulator of the growth of the exocrine pancreas [21] [22] [23] [24] [25] . Aberrant pancreasselective Wnt pathway overactivation resulting from pancreatic Apc (adenomatous polyposis coli) inactivation leads to pancreatomegaly [25] and the Wnt pathway is required for the regeneration that follows pancreatitis. Wnt pathway dysregulation can contribute to Kras-driven PDAC (pancreatic ductal adenocarcinoma) progression in mice [26] .
To identify new genes involved in the regulation of acinar cell homoeostasis, we searched for novel Ptf1a partners. Ptf1a is interesting in that its N-terminal region contains transactivation domains [13] and its C-terminal region lacks homology to other known proteins except for a conserved region that is present in Drosophila Fer1 [9] . Therefore we set up a yeast two-hybrid screen to uncover new Ptf1a C-terminus interactors. Among the gene products identified was ICAT (inhibitor of β-catenin and Tcf4), which was described previously as an important regulator of the Wnt pathway and cell proliferation [27] , but its function in the pancreas is unknown. In the present study, we show that ICAT interacts with Ptf1a in vitro and in vivo and it regulates PTF1-dependent transcriptional activity, in part, by perturbing P/CAFmediated Ptf1a acetylation. In addition, we show that its expression is altered in PDAC and is associated with patient survival.
MATERIALS AND METHODS

Plasmids
The following plasmids were used: ICAT-GST (glutathione transferase) [28] , β-catenin (given by A. García de Herreros, IMIM-Hospital del Mar, Barcelona, Spain); p6XA26-Luc, pcDNA3-Ptf1a-HA, pFLAG-CMV2-Ptf1a, pIRESneo-Ptf1a and Ptf1a deletion mutants were described previously [13] ; Ptf1a-GFP (green fluorescent protein) and Rbpjl (given by R.J. MacDonald, University of Texas Southwestern Medical Center, Dallas, TX, U.S.A.); and P/CAF-FLAG (given by H. SantosRosa, The Wellcome Trust/Cancer Research UK, Cambridge, U.K.). For the production of recombinant proteins, pGEX4T3-ICAT and pGEX6T3-Ptf1a were used. Plasmids Ela200-Luc and Ela500-Luc were generated by subcloning the luciferase cDNA downstream of the Ela200 and Ela500 elastase enhancers (obtained from R.J. MacDonald).
Antibodies
The following antibodies were used: mouse anti-FLAG M2 mAb (monoclonal antibody) (F3165; Sigma), mouse anti-HA (haemagglutinin) mAb (MMS-101P; Covance) and anti-tubulin antibody (T8203; Sigma); affinity-purified HRP (horseradish peroxidase)-conjugated anti-(mouse IgG) and anti-(rabbit IgG) (DAKO; Glostrup) antibodies; affinity-purified rabbit anti-Ptf1a antibody; rabbit anti-ICAT polyclonal antibody [28] ; mouse anti-ICAT mAb (ab57544; Abcam); and mouse anti-β-catenin mAb (610154; BD Biosciences).
Cell culture
Cells were cultured in DMEM (Dulbecco's modified Eagle's medium) supplemented with glutamine, 10 % fetal bovine serum, penicillin (100 units/ml) and streptomycin (100 mg/ml). Cells were transfected using Lipofectamine TM (Invitrogen), according to the manufacturer's instructions. Other reagents were from Sigma except for protease inhibitors (Complete TM , an EDTA-free protease inhibitor cocktail from Roche).
Yeast two-hybrid screening
For the LexA yeast two-hybrid assays, the baits were cloned into the pBTM116 plasmid (tryptophan marker) in-frame with a LexA DNA-binding domain. For the GAL4 yeast two-hybrid assays, the Ptf1a N coding fragment was subcloned from the Ptf1a N-pBTM116 plasmid. The ability of the resulting fusion proteins to activate transcription by themselves was tested. For the screening, a 20-22-week human fetal brain library (Clontech) and a whole mouse E (embryonic day) 9.5 cDNA library (J. Obata, Nara Institute of Science and Technology, Japan) [29] were used. The cDNA libraries, cloned into the pACT2 vector (Clontech), were introduced by LiAc transformation into the L40 reporter strain [MATa trp1-901 leu2-3, 112 his3-D200 ade2 LYS: (LexAop)4-HIS3 URA3: (LexAop)8-LacZ; 3] expressing the fusion protein LexA-Ptf1a N. Yeast transformants were selected on Trp-Leu-His plates and clones were isolated over 10 days following transformation. After isolation on Trp-LeuHis plates, clones were assayed for β-galactosidase activity by a semi-quantitative filter assay. For clones clearly showing β-galactosidase activity, the plasmid DNA was recovered and the sequence of the insert was analysed using BLAST.
Immunoprecipitation, co-immunoprecipitation, in vitro binding and Western blotting
HEK (human embryonic kidney)-293 cells were transfected with the desired plasmids and cells were lysed in 50 mM Hepes (pH 7.4), 5 mM MgCl 2 , 1 mM DTT (dithiothreitol), 100 mM NaCl, 2 mM EGTA and 1 % Triton X-100 for 15 min at 4
• C. Lysates were cleared by centrifugation for 10 min at 13 000 g and the supernatant was recovered. The indicated antibodies were added to the lysate supernatants together with Protein G-agarose and incubated overnight at 4
• C. Immune complexes were pelleted by centrifugation and washed with lysis buffer. Laemmli buffer was added to the samples and a portion of this material was fractionated using SDS/PAGE (10 % gel), transferred and blotted with specific antibodies. GST fusion proteins were purified from IPTG (isopropyl β-D-thiogalactopyranoside)-induced BL21 Escherichia coli cells using glutathione-Sepharose beads (GE Healthcare) and dialysed. To test the ability of Ptf1a to interact with putative partners in vitro, HEK-293 cells were transfected with pcDNA3-Ptf1a-HA. Cells were incubated for 15 min in lysis buffer on ice and lysates were cleared by centrifugation at 4
• C at 13 000 g. Lysates were incubated with 50 % glutathione-Sepharose beads (50 μl) in PBS and GST (25 μg) for 2 h at 4
• C. After preclearing, lysates were incubated overnight at 4
• C with glutathione-Sepharose beads and either GST or GST fusion proteins (10 μg). The beads were washed with ice-cold lysis buffer and resuspended in loading buffer. Ptf1a-associated proteins were detected by SDS/PAGE followed by immunoblotting using specific antibodies. Reactions were developed using chemiluminiscence [ECL (enhanced chemiluminescence) detection reagents, GE Healthcare].
Luciferase assays
HEK-293, 266-6 or AR42J cells were transfected with the luciferase reporter construct of interest (0.1 μg), Renilla luciferase pRL-TK vector (Promega) (15 ng) , and the test plasmids or the corresponding empty plasmids. Transfections were performed in triplicate using FuGENE ® 6 transfection reagent (Roche Applied Science). After transfection (24-48 h), cells were lysed and reporter activity was determined using the Dual Luciferase Assay system (Promega), following the manufacturer's instructions. Firefly and Renilla luciferase activities were measured using a luminometer.
qRT-PCR (quantitative real-time PCR) and gene expression
Total RNA was isolated using the Gen-elute TM mammalian total RNA miniprep kit (Sigma), treated with DNase I (Ambion), and cDNAs were prepared according to the manufacturer's instructions, using the TaqMan ® Reverse Transcription Reagents (Applied Biosystems ® , Roche). qRT-PCR analysis was performed using the SYBR Green PCR Master Mix and an ABI Prism ® 7900HT instrument (Applied Biosystems ® ). For the studies with stable clones, three independent RNA extractions were prepared and analysed in separate for each clone. A list with the sequence of the used primers is provided as Supplementary Table S1 (at http://www.biochemj.org/bj/451/bj4510395add.htm). Expression levels were calculated using the comparative method of relative quantification, using HPRT (hypoxanthine-guanine phosphoribosyltransferase) as normalizer. All experiments were performed at least three times independently.
Lentiviral infections
HEK-293 packaging cells were transfected with FG12 empty plasmid or the FG12-ICAT plasmid together with the corresponding helper vectors: pRSV-rev, pHCMV-G and pMDLgpRRE. After transfection, the culture medium was replaced and medium containing the released lentiviral particles was collected after 48 h and stored at 4
• C for further purification/concentration by ultracentrifugation at 47 000 g for 2 h at 16
• C in a swinging rotor. The lentiviral titre, determined in HEK-293 cells, was used to calculate the necessary dilution of lentiviral particles needed to virtually infect 100 % of the seeded cells. Transduction efficiency was monitored by direct fluorescence microscopy. CtrB1 (chymotrypsinogen B1) (fw, 5 -CAGAGCAGCTGTCC-TTTTCCCATGGG-3 and rv, 5 -GTCTCGTCGACAGG-AAAAGGGTACCC-3 ) and amyl (amylase) E-box C→T mutant (fw, 5 -CACAGTTTGAAGGTTCTTCAGAAA-3 and rv, 5 -GTGTCAACTTCCAAGAAGTCTTT-3 ). For the binding reactions, the buffer was prepared by adding components in the following order: 20 mM Tris/HCl, 60 mM KCl, 5 % glycerol, 500 nM DTT and 2 mM EDTA. The EMSA reactions were prepared by adding nuclear extracts (5 μg) to binding buffer plus poly(dI/dC) and IRDye oligonucleotide in the presence or absence of unlabelled competitor oligonucleotide. For the competition reactions, the unlabelled oligonucleotide was added first and the mixture was incubated on ice, before adding the IRDye-labelled corresponding oligonucleotide. For the supershift assays, the antibodies were added at the same time as the unlabelled competitor oligonucleotides. The EMSA reactions were then incubated for an additional 20 min at room temperature (22 • ) and loaded on to SDS/PAGE (5 % gel). Gels were scanned using the Odyssey Infrared Imaging System (Li-COR).
Generation of stable transfectants
The human FLAG-ICAT was cloned into the pREP4 vector. HEK-293 and 266-6 cells were transfected with either the pREP4-empty or the pREP4-FLAG-ICAT plasmid and selected for 14 days in complete DMEM supplemented with hygromycin; resistant cells were cloned by limiting dilution.
Immunofluorescence and immunohistochemical analysis
Immunofluorescence was performed in Cos7 and 266-6 cells that were fixed with 4 % PFA (paraformaldehyde) in PBS for 10 min at room temperature. After washing with PBS, cells were permeabilized for 20 min in 0.3 % Triton X-100 in PBS, washed with PBS and incubated with 1 % BSA in 0.3 % Triton X-100 for 45 min at room temperature. Cells were incubated with the primary antibody for 1 h at room temperature, washed with PBS, incubated with the secondary antibodies for 40 min, washed and mounted.
The immunohistochemical expression of ICAT (rabbit polyclonal antibody) and β-catenin was assessed on TMAs (tissue microarrays) of formalin-fixed paraffin-embedded samples containing ACCs (acinar cell carcinomas) (n = 11) and PDAC (n = 93) generated at the University of Verona, Italy. Four cores represented each tumour. The local Ethics Committee approved all studies. Sections were deparaffinized, rehydrated and antigen retrieval was performed by boiling in citrate buffer (pH 6.0) for 10 min; endogenous peroxidase was inactivated with 3 % H 2 O 2 in methanol. The sections were incubated in 2 % BSA and 0.5 % Triton X-100 in PBS for 1 h, then rinsed and incubated with specific antibodies. Reactions were developed by adding the Envision secondary reagent (DAKO) for 40 min, followed by washing with PBS. DAB (diaminobenzidine) was used as a chromogen. After washing, sections were stained lightly with haematoxylin and dehydrated. All samples were processed using the NovoLink Polymer Detection System (Novocastra Laboratories). Sections incubated without the primary antibody served as a negative control. Slides were scanned with ScanScope GL System (Aperio Technologies) and visualized using ImageScope Software (Aperio Technologies).
Statistical analysis
Categorical data were analysed by Fisher's exact test; the distribution of continuous variables was reported as median and IQR (interquartile range) (25th-75th percentiles). Continuous data were tested for normality after grouping and analysed by either unpaired Student's t test or Mann-Whitney test. Univariate survival analysis was accomplished comparing Kaplan-Meier curves by Mantel-Cox log-rank test. Multivariate survival analysis was performed by Cox proportional hazards regression; selection of the best model used the 'backward elimination' algorithm. For all the analyses, P < 0.05 was considered as statistically significant. Graphs and analyses were produced using both MedCalc ® 12 (MedCalc Software; http://www.medcalc.org) and R (version 2.10; http://www.r-project.org].
RESULTS
Screening for new Ptf1a interactors
To identify new Ptf1a interactors, four baits coding for different regions of Ptf1a were prepared: N-terminus including the bHLH domain (residues 1-214, Ptf1a C), C-terminus with or without the bHLH domain (residues 162-326, Ptf1a N; and/or residues 211-326, Ptf1a N + bHLH) and the full-length Ptf1a protein (residues 1-326). The baits were fused to the LexA-binding domain and cloned in the pBTM116 plasmid. As a control, L40 yeast cells were co-transformed with plasmids coding for Rbpj, a known Ptf1a interactor, fused to a GAL4 transcription activation domain and with the LexA-Ptf1a N + bHLH bait. Both reporter genes were effectively activated, indicating that the system allowed the isolation of novel Ptf1a interacting proteins.
The N-terminus of Ptf1a and the full-length construct gave a strong positive β-galactosidase activity in the absence of prey, in agreement with our previous report that the N-terminal region comprises a transcriptional activation domain [13] . The remaining bait constructs did not activate the reporter genes by themselves. Several in-frame inserts of interest were identified in the screening performed with yeast transformed with LexA-Ptf1a N + bHLH plasmid and the human fetal brain cDNA library or whole mouse embryo library (Table 1) . Among them were the known Ptf1a interactors Rbpj, E2A and Tcf12/HEB, thus confirming the efficacy of the screening strategy. The sequences of Midkine and Pleiotrophin, two highly related proteins that have been reported to have both secreted and nuclear functions [30] , were identified in five independent clones and the interaction of Midkine with Ptf1a was confirmed using in vitro pull-down assays (results not shown). Meis-related sequences were also identified; Meis2b is part of the transcriptional complex binding to the B element of Figure 1 The C-terminal domain of Ptf1a interacts with ICAT (A) HEK-293 cells were transfected with the indicated expression plasmids. After 36 h, cell extracts were subjected to a pull-down assay using ICAT-GST recombinant protein followed by a Western blot (WB) against Ptf1a and β-catenin. (B) HEK-293 cells were transfected with the indicated expression plasmids; after 36 h cell lysates were immunoprecipitated (IP) with anti-FLAG beads followed by Western blotting using the anti-FLAG M2 antibody. Ptf1a and ICAT were analysed by Western blot. (C) HEK-293 cells were transfected with the indicated expression plasmids. After 36 h, cell extracts were subjected to a pull-down assay, using ICAT-GST recombinant protein followed by Western blotting against Ptf1a. acinar genes [31] . However, we could not confirm an interaction of Meis2b with Ptf1a using pull-down assays because the former showed non-specific binding to GST.
ICAT is a new Ptf1a partner
One of the isolated inserts encoded ICAT. To confirm the interaction, we performed a GST pull-down assay. Total lysates from HEK-293 cells transfected with expression plasmids for Ptf1a with or without β-catenin were incubated with recombinant ICAT-GST protein; β-catenin was used as a positive control. Ptf1a was successfully and specifically pulled down with ICAT-GST. Interestingly, β-catenin reduced the binding of Ptf1a to ICAT, indicating a possible competition ( Figure 1A ). Ptf1a and ICAT were also co-immunoprecipitated from the extracts of HEK-293 cells co-transfected with plasmids coding for both proteins ( Figure 1B) . To map the region of Ptf1a that binds ICAT, deletion mutants were used in pull-down assays ( Figure 1C ). Ptf1a 270-326 and Ptf1a 296-326 fragments retained the ability to interact with ICAT-GST, whereas the Ptf1a 236-326 fragment did not, supporting that ICAT interacts with Ptf1a in a region comprising residues 236-270. 
ICAT interferes with the transcriptional activity of the PTF1 complex in vitro and in vivo
To determine whether ICAT affects the transcriptional activity of the PTF1 complex, we analysed the effect of ICAT overexpression on the activity of the 6XA26-luciferase synthetic reporter construct in HEK-293 cells, or in acinar AR42J and 266-6 cells, transiently co-transfected with Ptf1a and Rbpjl. ICAT repressed the transcriptional activity of the PTF1 complex (Ptf1a-Rbpjl) in a dose-dependent manner (Figures 2A and 2B ). Similar effects were observed when the reporter assays were performed in AR42-J or 266-6 cells, both displaying acinar differentiation. ICAT also repressed the activity of the PTF1 complex using the endogenous Ela-luciferase promoter reporter constructs (Ela200-Luc and Ela500-Luc) ( Figure 2B ).
To assess whether β-catenin might affect the effects of ICAT on the activity of the enhancer reporter constructs, we used 266-6 cells in which endogenous β-catenin is found in the membrane/cytosol, but not in the nucleus. β-Catenin overexpression did not affect the activity of the 6XA26 reporter. Moreover, co-transfecting β-catenin with ICAT expression plasmids did not affect the repressive effects of ICAT on the reporter ( Figure 2C ). Therefore we conclude that ICAT interferes with the PTF1 transcriptional activity in a β-catenin-independent manner.
To further assess the effects of ICAT on the acinar differentiation programme, stable clones of 266-6 cells overexpressing ICAT-FLAG were obtained ( Figure 3A) . Expression of endogenous and exogenous ICAT mRNA was discriminated using specific primers by qRT-PCR ( Figure 3B) ; protein expression was analysed by Western blotting and immunofluorescence ( Figures 3A and 3D) . The clones overexpressing ICAT consistently showed low expression levels of several mRNAs of PTF1 targets, such as Amyl and CtrB1, but there was no effect on elastase or on Ptf1a or Rbpjl transcripts. By contrast, mRNA levels of CpA, a marker of pancreatic multipotent progenitors [32] , were increased. An up-regulation of the developmental markers Pdx1 and Sox9 expressed in pancreatic progenitors was observed in the four independent clones analysed ( Figure 3C ), suggesting that ICAT promotes an embryonic phenotype. Levels of transcripts coding for endocrine markers were unaffected.
In all of the stable clones studied, ICAT displayed a similar subcellular distribution. Following ICAT overexpression, β-catenin localization ( Figure 3D ) and transcriptional activity ( Figure 3E) , assessed using the TOPFlash and FOPFlash luciferase reporters, were unchanged. These findings further support that the effects of ICAT on the acinar programme are not mediated by its interaction with β-catenin.
ICAT is present in a reconstituted PTF1 complex and it reduces Rbpjl binding and impairs P/CAF-mediated Ptf1a acetylation
To determine whether ICAT can bind to the PTF1 complex and thus regulate expression of genes coding for digestive enzymes, oligonucleotides encompassing the PTF1-binding sites on the corresponding promoters were used for EMSAs. IRDyelabelled oligonucleotides were incubated with nuclear extracts from HEK-293 cells expressing Ptf1a and Rbpjl ( Figure 4A ). As expected, a specific shift of the CtrB1, CpA1 and Amyl2 IRDye oligonucleotides was detected, which was absent when the nuclear extracts were pre-incubated with non-labelled competitor oligonucleotides. When cells were co-transfected with a plasmid coding for ICAT, the PTF1 complex retained the ability to bind to the oligonucleotides ( Figure 4B ). Monoclonal anti-ICAT antibodies, but not control anti-(mouse IgG) antibody, induced a supershift of the PTF1 complex bound to the CtrB1-IRDye oligonucleotide in a dose-dependent manner ( Figure 4C ), indicating the presence of ICAT in the reconstituted PTF1 complex. To further analyse whether ICAT perturbs PTF1 complex formation, we used co-immmunoprecipitation with pancreas-specific PTF1 components, P/CAF and ICAT. As shown in Figure 5(A) , the presence of ICAT reduced the amount of Rbpjl bound to complex ( Figure 5A ). To assess whether ICAT could interfere with the subcellular distribution of Ptf1a in transfected HEK-293 cells, immunofluorescence was used. On ICAT overexpression, the nuclear localization of Ptf1a and β-catenin were unaffected ( Figure 5B , and Supplementary Figure S1 at http://www.biochemj.org/bj/451/bj4510395add.htm). One mechanism through which ICAT inhibits β-catenin transcriptional activity is the inhibition of its binding to the CBP (CREB-binding protein)/p300 transcriptional co-activator [33] . Because the histone acetyltransferase P/CAF is required for maximal transcriptional activity of the PTF1 complex on the promoters of genes coding for digestive enzymes, we assessed whether ICAT could interfere with the PTF1 activity by impairing its interaction with P/CAF or by impairing the acetylation of Ptf1a or Rbpjl. ICAT overexpression inhibited the interaction Ptf1a and P/CAF in a dose-dependent manner ( Figure 6A ) and, consequently, it impaired Ptf1a acetylation as well as P/CAF autoacetylation ( Figure 6B ), indicating that this mechanism may contribute to its effects on the exocrine programme. There was 
no detectable acetylation of Rbpjl under either condition tested (results not shown).
Immunohistochemical analysis of ICAT expression in normal pancreas and pancreatic tumours
The finding that ICAT affects exocrine differentiation prompted the analysis of ICAT expression in the normal human pancreas and in pancreatic tumours. Immunohistochemistry showed that ICAT displays a highly cell-type-specific expression in the normal pancreas (n = 6): in acinar and endocrine cells it was found exclusively in the nucleus, whereas in ductal cells it was almost exclusively cytoplasmic with only rare and scattered positive nuclei ( Figure 7A, panels a-d) .
Ten of eleven ACC had ICAT expressed in nuclei as in normal acini, the remaining case had a strong cytoplasmic positivity with unstained nuclei; four tumours showed strong β-catenin nuclear expression, but there was no relationship with the level or distribution of ICAT.
In PDAC samples (n = 93) (Tables 2 and 3 ), 43 cases (46.2 %) showed aberrant nuclear staining ('acinar-like' pattern) ( Figure 7B , panel b) and three cases (3.2 %) displayed cytoplasmic staining similar to that seen in normal ducts with negative or focally positive nuclei ('ductal-like' pattern) ( Figure 7B, panel a) . A more heterogeneous staining pattern was observed in 45 tumours (48.4 %): in 17 cases (18.3 %), areas containing cells with nuclear or cytoplasmic ICAT expression were juxtaposed ('patchy' pattern) ( Figure 7B, panel c) ; in 28 cases (30.1 %) the two staining types were interspersed ('mixed' pattern), with cancer cells displaying positive nuclei, positive cytoplasm or both ( Figure 7B, panel d) . The remaining two tumours lacked ICAT expression.
To examine the association of ICAT staining pattern with the clinicopathological features of the patients, tumours lacking ICAT expression or displaying the 'ductal-like' pattern were excluded due to small sample size. Tumours of grade G1 (n = 1) and G2 were analysed jointly, as were those of stage IB (n = 1) and stage
Figure 6 ICAT inhibits the binding of P/CAF to Ptf1a
(A) HEK-293 cells were transfected with the indicated expression plasmids. At 36 h post-transfection, cell extracts were immunoprecipitated (IP) using rabbit anti-Ptf1a or control normal rabbit serum (NRS). Binding of P/CAF to Ptf1a was assessed using specific antibodies against P/CAF or Ptf1a. The total levels of Flag-Ptf1a and P/CAF were assessed by Western blotting (WB). (B) HEK-293 cells were transfected with 3 μg of each of the plasmids, P/CAF-FLAG, Ptf1a-FLAG and ICAT-FLAG. After 36 h post-transfection, cell extracts were immunoprecipitated using anti-FLAG-conjugated beads; the acetylation status of Ptf1a and P/CAF were assessed by Western blotting using anti-acetyl-lysine (AcLys) antibodies. IIA. Patients with stage III and IV unresectable tumours were also analysed together. The results are summarized in Table 3 . A 'mixed' staining pattern was preferentially associated with G3 tumours (P = 0.04). 
ICAT 'acinar-like' staining pattern is associated with poorer survival in PDAC patients
To investigate the association of ICAT expression with overall survival, we first compared Kaplan-Meier curves using ICAT tumour staining patterns. Median survival was 21.7, 17.4 and 13.6 months for patients with 'mixed', 'patchy' and 'acinar-like' ICAT staining respectively. The differences in survival of patients with tumours having 'mixed' and 'acinar-like' patterns were statistically significant (P = 0.022, log-rank analysis) (Figure 8 ).
To assess whether ICAT tumour staining pattern was an independent predictor of survival, a multivariate analysis was performed. The other variables included were age, gender, tumour stage and grade. The independent predictors of poor survival were tumour stage III/IV (unresectable tumour, P = 0.017), 'acinarlike' ICAT staining (P = 0.001) and, to a minor extent, a 'patchy' ICAT staining (P = 0.04) ( Table 4 ). 
DISCUSSION
Ptf1a is a critical regulator of pancreatic development, differentiation and function. Little is known about the mechanisms that are involved in the regulation of its expression at the gene level or about the regulation of protein function. Proteins of the HES (Hairy and Enhancer of Split) family interact with Ptf1a and downregulate the transcriptional activity of the PTF1 complex [34] . The N-and C-terminal domains of Ptf1a display low homology with other proteins, which hampers the inference of potential mechanisms of regulation. We therefore set out to identify novel partners using a yeast two-hybrid strategy. We used two different embryo libraries and identified several novel putative partners whose biochemical interactions were validated using pull-down assays. In the present study, we focus on ICAT because this protein is a known regulator of the Wnt pathway which plays a crucial role in pancreatic development, differentiation and carcinogenesis [23] . ICAT interacts directly with the C-terminal domain of Ptf1a; using GST pull-down assays, we mapped this interaction to residues 236-270 of Ptf1a, a region that shows an 87 % identity in mammals (human, dog, rat and mouse) and contains a subregion of 16 residues that are absent in Xenopus laevis and Danio rerio. Two small regions in the C-terminal domain are highly phylogenetically conserved and their alteration affects the binding of the Rbpj/Rbpjl partners: deletions or alterations in the C1 region (HSLSW) affected the binding of Rbpjl more than that of Rbpj, whereas alterations in the C2 (WTPEDPR) region affected exclusively Rbpj [9] . Residues 246-273, which are conserved in vertebrates, but not in insects, are crucial for the binding of Rbpjl, but not of Rbpj.
Our data indicate that ICAT overexpression induces important changes in the expression of pancreatic genes, through several mechanisms. ICAT reduces the binding of Rbpjl to Ptf1a and it also perturbs the binding of P/CAF and Ptf1a acetylation, thus down-regulating the expression of several genes coding for digestive enzymes that are regulated by the PTF1 complex. Interestingly, not all genes regulated by PTF1 were equally affected. In addition, ICAT overexpression was associated with a consistent and significant up-regulation of the expression of Pdx1 and Sox9. Both transcriptional regulators are preferentially expressed in non-acinar cells in the pancreas during development and in the adult organ [35] . These findings, together with the up-regulation of CpA, further suggest that ICAT overexpression shifts the differentiation programme of acinar cells towards a less mature stage. The mechanisms leading to the up-regulation of Pdx1 and Sox9 will require further investigation. We could not assess the effects of Icat knockdown in 266-6 acinar cells because of the undetectable basal expression of the protein in these cells, which hampers the evaluation of the quality of the interference assays (results not shown).
Regarding its role in vivo, Icat-null mice have been generated and display multiple defects in the forebrain and craniofacial bones and absent kidneys due to a lack of ureteral bud branching and apoptotic death of mesenchymal metanephros cells [36, 37] . Histological analysis of the pancreas of Icat-null mice failed to show abnormalities (results not shown), but more detailed studies might be required to detect a mild phenotype. We have reported previously that pancreatic ICAT protein levels are modulated during ageing and may contribute to the phenotype observed in mice in which Apc is selectively deleted in the pancreatic epithelium [25] .
ICAT has been shown to modulate transcriptional regulation in other systems. In prostate cancer cells, it potentiates the liganddependent effects of androgens through the formation of a ternary complex involving the androgen receptor and β-catenin [38] . In contrast, our findings support the notion that its effects on pancreatic exocrine differentiation are independent from its role as a regulator of Wnt function. We cannot rule out additional Wntdependent effects that may not be unravelled using 266-6 cells since luciferase reporter assays indicate low level Wnt pathway activity in these cells.
Little is known about the regulation of ICAT at the transcriptional or post-transcriptional levels. In intestinal cells, progastrin knockdown leads to ILK (integrin-linked kinase) down-regulation, which, in turn, results in the induction of ICAT and the repression of β-catenin/Tcf4 transcriptional activity and tumour growth. In mice where one allele of Apc was inactivated in the intestine, progastrin depletion was associated with reduced tumorigenesis and increased goblet cell differentiation and apoptosis [39] . These findings are potentially relevant to pancreatic acinar tumours: CCK (cholecystokinn), a gastrin analogue, is a major regulator of acinar cell function, and the Wnt pathway is commonly activated in these tumours through a variety of mechanisms, including β-catenin mutations [40] . However, in the present study, we found no relationship between nuclear β-catenin and ICAT expression.
The effect of ICAT on acinar cell differentiation, with the upregulation of developmental genes such as Sox9 and Pdx1, also suggests a possible role in tumours. Pasca de Magliano et al. [41] showed that ICAT overexpression in cultured PDAC cells led to reduced Wnt transcriptional activity, reduced cellular proliferation and an increase in apoptosis; the subcellular distribution of ICAT and its effect on cellular differentiation were not assessed. In the present study, we analysed in greater detail the expression of ICAT in pancreatic tumours and we find that in addition to expression levels, subcellular localization of the protein may play an important role in its function. Nuclear ICAT was independently associated with prognosis in patients with PDAC, but the mechanisms involved therein are not known.
In conclusion, ICAT modulates PTF1 function through the regulation of Ptf1a acetylation and it induces an up-regulation of the developmental markers Pdx1 and Sox9. ICAT expression and subcellular distribution are associated with the outcome of patient with PDAC. It remains to be determined whether this association is related to the activation of Wnt pathway in pancreatic tumours.
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